Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma
Status:
Not yet recruiting
Trial end date:
2028-12-30
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, open-label, exploratory trial of temozolomide-based
chemo-radiotherapy which compares two widely used established radiation schedules with either
40 Gy in 15 fractions or 25 Gy in 5 fractions with concurrent temozolomide for both schedules
in patients with glioblastoma.